Navamedic Reports Full Year 2023 Earnings

Navamedic (OB:NAVA) Full Year 2023 Results

Key Financial Results

• Revenue: kr512.0m (up 34% from FY 2022).
• Net income: kr3.81m (down 87% from FY 2022).
• Profit margin: 0.7% (down from 7.7% in FY 2022). The decrease in margin was driven by higher expenses.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Navamedic Earnings Insights

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Pharmaceuticals industry in Europe.

Performance of the market in Norway.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 3 warning signs for Navamedic (1 is concerning!) that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.